Gaudium IVF & Women Health IPO Review: Should You Subscribe or Avoid?
.png)
TL;DR
- Gaudium IVF IPO priced at ₹75–79 values the company at about 28–30x FY25 earnings.
- Strong revenue growth and ~40% EBITDA margin show healthy profitability.
- Company operates 30+ fertility centers using a scalable hub-and-spoke model.
- Key risks include tax dispute, skilled staff dependency, and healthcare litigation exposure.
Gaudium IVF & Women Health IPO Review: Should You Subscribe or Avoid?
4
The Gaudium IVF & Women Health IPO Review is gaining attention among investors looking for niche healthcare listings. India’s fertility services industry is expanding quickly due to rising infertility awareness, delayed parenthood, and improving affordability. Companies operating in specialized healthcare segments often command premium valuations because of strong margins and entry barriers.
But does this IPO truly deserve a place in your portfolio, or is it priced too aggressively? Let’s break down everything investors should know before applying.
Company Overview
Gaudium IVF & Women Health Limited operates in assisted reproductive technology services, offering treatments such as IVF, ICSI, and IUI. The company has built a pan India presence with more than 30 centers structured through a hub-and-spoke model, allowing centralized expertise while expanding reach efficiently.
Founded by fertility specialist Dr. Manika Khanna, the company positions itself as a specialized fertility brand with standardized clinical protocols and stage wise treatment processes.
Unlike diversified hospital chains, Gaudium focuses only on fertility care, giving it a niche identity and operational specialization.
IPO Details at a Glance
Here are the key IPO details explained simply:
- Price band is ₹75 to ₹79 per share.
- Total issue size is ₹575.02 crore.
- Minimum lot size is 189 shares.
- Shares will list on the BSE and NSE.
- Issue opens on February 20, 2026 and closes on February 24, 2026.
- Tentative listing date is February 27, 2026.
Reservation structure
- Qualified Institutional Buyers receive 50 percent allocation.
- Non Institutional Investors receive 15 percent.
- Retail investors receive 35 percent.
Financial Performance Snapshot
The company has demonstrated strong growth over the last three financial years.
- Revenue grew from ₹44.23 crore in FY23 to ₹47.89 crore in FY24 and jumped to ₹70.72 crore in FY25.
- Net profit was ₹13.53 crore in FY23, dipped to ₹10.32 crore in FY24, and rose sharply to ₹19.13 crore in FY25.
- Net worth increased from ₹22.73 crore in FY23 to ₹26.99 crore in FY24 and reached ₹46.30 crore in FY25.
- EBITDA margin remained strong at about 45.36 percent in FY23, 40.25 percent in FY24, and 40.48 percent in FY25.
A major highlight is profit growth of about 85 percent year on year in FY25, showing operational leverage as the company scales.
High margins near 40 percent are uncommon in healthcare services and indicate strong pricing power and efficient cost control.
Objects of the Issue
IPO proceeds will be used for:
- Setting up new IVF centers
- Repayment of certain loans
- General corporate purposes
Expansion funding is often viewed positively because it supports revenue visibility. However, debt repayment suggests previous capital intensity.
Competitive Positioning
Interestingly, there are no direct listed peers in India operating purely in fertility services.
For comparison, international players include:
- Progyny Inc.
- Inspire IVF Public Company
This lack of domestic peers gives Gaudium a scarcity premium. Investors often pay higher multiples for companies operating in underrepresented sectors on stock exchanges.
Key Strengths Investors Should Note
Strong clinical expertise
Specialist driven fertility treatment enhances success rates and builds patient trust.
Scalable expansion model
The hub-and-spoke strategy allows rapid geographic growth without proportionate cost escalation.
Digital adoption
Telemedicine and lab automation improve operational efficiency and patient reach.
Growing market opportunity
India’s fertility industry is expanding quickly due to rising infertility rates, lifestyle changes, and increasing awareness.
Risks You Should Not Ignore
Every IPO carries uncertainties, and this one is no exception.
Tax dispute
The company faces a ₹31 crore tax dispute, which could affect earnings visibility if unfavorable outcomes occur.
Dependence on skilled professionals
Fertility treatment success depends heavily on experienced doctors and embryologists. High attrition could impact operations.
Healthcare sector risks
Litigation, regulatory scrutiny, and compliance requirements are inherent to medical businesses.
Past cash flow pressure
Historical negative cash flows and rising borrowings could affect financial flexibility.
Valuation Analysis
At the upper band price of ₹79, the IPO is valued at around 28–30 times FY25 earnings.
For context, this valuation is considered premium for a small healthcare company. However, investors often accept higher multiples for niche healthcare leaders with high margins and strong growth visibility.
Its pre IPO EPS stands at ₹3.12 with a post issue P/E of about 25.36.
So the valuation debate comes down to one question:
Are you willing to pay a premium today for future growth?
Market Context: Why This IPO Matters
Healthcare IPOs in India have historically attracted strong investor interest, especially when they represent unique segments. Fertility services are still underpenetrated in India compared with developed countries.
If the company executes its expansion well, it could become a dominant listed fertility platform. For investors seeking sector diversification beyond IT, banking, or FMCG, this IPO offers exposure to a niche healthcare theme.
Who Should Consider Applying
This IPO may suit investors who:
- Prefer niche sector opportunities
- Have a medium to long term horizon of 2 to 3 years
- Can tolerate moderate risk
It may not suit short term listing gain seekers because premium valuations can limit upside on debut.
Expert Verdict
The Gaudium IVF & Women Health IPO Review suggests a balanced outlook.
Positives
- Strong profitability
- Growing industry
- Scalable model
Concerns
- Premium pricing
- Legal and operational risks
Overall, the issue appears suitable for investors willing to hold long term rather than those seeking quick gains.
FAQs
Is Gaudium IVF IPO good for listing gains?
Not ideal. Premium valuation reduces chances of sharp listing upside.
What is the minimum investment amount?
One lot of 189 shares at ₹79 equals about ₹14,931.
Is the company profitable?
Yes. It reported ₹19.13 crore net profit in FY25.
What is the biggest risk?
The ₹31 crore tax dispute and dependence on specialized doctors.
Does it have listed competitors in India?
No. It is currently a rare pure play fertility services listing.
Final Thoughts
The IPO presents a classic growth versus valuation tradeoff. The business fundamentals are strong, but pricing leaves limited margin of safety. Investors who believe in India’s fertility healthcare growth story may consider subscribing with patience.
For data driven IPO analysis, research backed insights, and seamless investing tools, Swastika Investmart Limited offers a reliable platform backed by SEBI registration, advanced analytics, investor education resources, and responsive support.
.webp)
.webp)
.webp)
